Baird lowered the firm’s price target on Illumina (ILMN) to $90 from $127 and keeps a Neutral rating on the shares. The firm updated its model following the China Ministry of Commerce ban on imports of gene sequencers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Target reports Q4 beat, Walgreens reportedly near go-private deal: Morning Buzz
- Illumina doesn’t seem to be blocked from offering services in China, says Stifel
- Morning Movers: Target, Best Buy slipping after earnings as tariffs take effect
- China’s CM adds 10 American companies to ‘unreliable entry’ list, WSJ says
- Citi cuts Illumina target, places on ‘negative catalyst watch’